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ABSTRACT
Background: Whether regional analgesia techniques have favorable impact on 
prognosis after cancer surgery is unclear, and existing reports show controversial 
results. The aim of the present study was to evaluate and compare recurrence and 
mortality between patients that received either intravenous (IV) or epidural patient 
controlled analgesia (PCA) for pain control after curative surgery for gastric cancer. 
Materials and methods: Medical records of patients that underwent curative 
gastrectomy for gastric cancer between November 2005 and December 2010 
were reviewed. Identified patients were categorized according to the use of IV or 
epidural PCA for postoperative analgesia. Demographic and perioperative variables 
including type of PCA were analyzed by univariate and multiple regression analysis to 
investigate any association with recurrence and mortality after surgery. Propensity 
score matching was done to adjust for selection bias.  
Results: Of the 3,799 patients included in this analysis, 374 and 3, 425 patients 
received IV and epidural PCAs, respectively. No difference in recurrence (HR, 1.092; 
95% CI 0.859 to 1.388; P = 0.471) or mortality (HR, 0.695; 95% CI 0.429 to 1.125; 
P = 0.138) was identified between the use of IV and epidural PCA. Propensity score 
matching also showed no difference in recurrence (HR, 1.098; 95% CI 0.756 to 1.596; 
P = 0.623) or mortality (HR, 0.855; 95% CI 0.391 to 1.869; P = 0.695) between the 
two groups. 
Conclusions: Postoperative use of epidural analgesia was not found to be 
associated with reduced recurrence or mortality after curative surgery in gastric 
cancer patients. This finding needs to be confirmed with prospective studies in the 
future.
INTRODUCTION
The notion that perioperative regional anesthesia 
and analgesia may improve cancer prognosis first emerged 
roughly a decade ago, [1–3] and was met by genuine 
enthusiasm of the anesthesia society. However, a decade 
later, we are still at a shortage of meaningful evidence 
to either support or refute this hypothesis. The difficulty 
of performing a large scale randomized controlled trial 
(RCT) with a relatively long follow-up period has led us to 
first look at the available data, and we have been presented 
with a number of retrospective [1, 2, 4–15] and very few 
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prospective [6, 16] studies done on the effect of regional 
anesthesia and/or analgesia on the prognosis of different 
types of cancer. 
Among several regional techniques, epidural 
analgesia is the most commonly employed method for 
operations performed in the abdominopelvic region. 
While there is relative abundance of retrospective and 
observational studies done on the effect of epidural 
analgesia in prostate [1, 5, 6, 8, 17–20] and colorectal 
cancer, [12, 13, 21–24] there are only a few that 
investigate gastric cancer, [4, 14, 15, 25] despite it being 
the fifth most common cancer worldwide. Moreover, not 
only do the existing studies report inconsistent results, 
most are based on the data of an insufficient number of a 
rather heterogeneous group of patients. The primary goal 
of this retrospective study was to compare the effect of 
postoperative epidural patient-controlled analgesia (PCA) 
vs. intravenous (IV) PCA, on recurrence and mortality in 
patients that received curative surgery with homogeneous 
surgical treatment at a high-volume center. 
RESULTS 
Study population, demographic data and 
perioperative characteristics 
Figure 1 shows the flowchart of patient sample 
selection. The data of 4, 098 patients were reviewed for 
analysis. Among these patients, 106 cases that received 
preoperative chemotherapy and 171 cases that underwent 
non-curative surgery were excluded. Additionally, 6 
cases of laparoscopic gastrectomy that were converted to 
laparotomy, 3 cases of unclear analgesia method, and 13 
cases of patient death within 30 days after surgery were 
excluded from analysis. 
The remaining 3, 799 cases with 374 in the IV PCA 
group and 3, 425 in Epidural PCA group were compared 
and analyzed. The opioid used in both type of PCAs was 
fentanyl, and all epidural PCAs contained ropivacaine. 
Ropivacaine was infused at a concentration of 0.15% 
and mixed with fentanyl at a dose of between 2–4 μg/
mL at basal rates of 4–5 mL/hr, bolus doses of 1–2 mL, 
and lock-out times of 15 minutes. All patients were 
anesthetized with balanced anesthesia which consisted of 
the use of a volatile anesthetic and remifentanil infusion 
at rates between 0.1–0.3 mcg/kg/min. Demographic 
characteristics of the patients are listed in Table 1. When 
comparing the demographic characteristics between the 
two groups, there was no difference in sex, height, weight, 
presence of hypertension, pulmonary, and liver diseases. 
However, there was a significant difference in age, and the 
presence of DM, cardiac, renal and neurologic diseases 
between the two groups. Greater cancer recurrence 
was seen with higher cancer stage (P = 0.012), but no 
difference was observed in tumor histology or resection 
method between the two groups. 
Enflurane, isoflurane and N2O were anesthetics 
that were more often used in the Epidural PCA group, 
while sevoflurane was more commonly used in the IV 
PCA group. Among other perioperative characteristics, a 
significantly greater proportion of patients of the IV PCA 
group were found to receive NSAIDs, phenylephrine, 
esmolol, labetalol and nicardipine than the Epidural 
PCA group, while ephedrine was more commonly used 
in the Epidural PCA group. There was no difference 
in intraoperative administration of colloids or packed 
RBC. Patients were followed up after surgery once 
every 3 months during the first year, every 6 months 
for the following 2 years, and every year thereafter for 
the duration of the scheduled follow-up period. Cancer 
recurrence occurred in 81 (21.7%) patients of the IV PCA 
group and 585 (17.1%) patients of the Epidural PCA 
group, and the mean time to recurrence was 564.34 ± 
404.0 and 545.2 ± 452.7 days in the IV PCA and Epidural 
PCA groups, respectively, with no significant difference 
(P = 0.717). Mortality occurred in 90 (24.1%) and 641 
(18.7%) patients of the IV PCA and Epidural PCA groups, 
respectively. The mean follow-up time in all of the patients 
was 53.3 ± 21.7 months. 
Association between analgesia method and 
cancer recurrence and mortality after surgery 
Kaplan–Meier curves for recurrence and mortality 
of patients with IV PCA vs. epidural PCA are shown in 
Figure 2.
Neither IV nor epidural PCA was found to be 
associated with cancer recurrence after surgery (HR, 1.092; 
95% CI, 0.859 to 1.388; P = 0.471) (Table 2). Factors that 
were related to lower recurrence were younger age and 
lower cancer stage. Total gastrectomy was found to be 
associated with greater risk of recurrence compared to 
subtotal gastrectomy (HR, 1.333; 95% CI, 1.132 to 1.569; 
P = 0.001). None of the anesthetics or other perioperative 
drugs were found to be associated with cancer recurrence. 
Type of postoperative PCA was also not found to be 
associated with mortality after open gastrectomy (P = 
0.138) (Table 3). Other variables associated with greater 
mortality included older age, higher cancer stage, total 
gastrectomy and the administration of intraoperative 
phenylephrine, norepinephrine and labetalol. 
In our PSM analysis, there was no difference in 
recurrence and mortality between the two groups (P = 
0.623 and P = 0.695, respectively) (Table 4). 
DISCUSSION
The perioperative period during which the patient 
is in the hands of the anesthesiologist is considered 
as a narrow window of opportunity where outcome 
after surgery may be affected by the choice of drugs 
and method of anesthesia and/or analgesia. [26] While 
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Table 1: Demographic and perioperative characteristics 
IV PCA
(n = 374)
Epidural PCA
(n = 3,425) P-value
Age (years) 59.6 ± 11.6 57.5 ± 11.7 0.001
Male sex, n 242 (64.7) 2,280 (66.6) 0.489
Height (cm) 163.4 ± 8.3 164.0 ± 8.6 0.187
Weight (kg) 62.8 ± 11.0 62.6 ± 10.0 0.678
Comorbidities
 HTN 108 (28.9) 916 (26.7) 0.390
 DM 64 (17.1) 398 (11.6) 0.003
 Pulmonary disease* 8 (2.1) 58 (1.7) 0.529
 Cardiac disease† 35 (9.4) 102 (3.0) < 0.001
 Renal disease‡ 16 (4.3) 23 (0.7) < 0.001
 Liver disease§ 20 (5.3) 141 (4.1) 0.278
 Neurologic diseaseǁǁ 21 (5.6) 47 (1.4) < 0.001
Cancer stage 0.012
 I 175 (46.8) 1,867 (54.5)
 II 83 (22.2) 605 (17.7)
 III 116 (31.0) 953 (27.8)
Tumor histology 0.052
 AWD 38 (10.2) 416 (12.1)
 AMD 114 (30.5) 988 (28.8)
 APD 132 (35.3) 1126 (32.9)
 Mucinous 11 (2.9) 87 (2.5)
 SRC 61 (16.3) 716 (20.9)
 Other 18 (4.8) 92 (2.7)
Lymphovascular invasion 130 (34.8) 1216 (35.5) 0.820
Resection method 0.241
 Subtotal 265 (70.9) 2,527 (73.8)
 Total 109 (29.1) 898 (26.2)
Anesthetic 
 Desflurane 67 (17.9) 492 (14.4) 0.077
 Enflurane 0 (0) 70 (2.0) 0.002
 Isoflurane 87 (23.3) 1,032 (30.1) 0.006
 Sevoflurane 220 (58.8) 1,825 (53.3) 0.043
 N2O 14 (3.7) 439 (12.8) < 0.001
 Propofol 1% 295 (78.9) 2,608 (76.1) 0.249
 Thiopental sodium 76 (20.3) 763 (22.3) 0.431
Other perioperative drugs 
 Aspirin 2 (0.5) 7 (0.2) 0.220
 NSAIDs 225 (60.2) 1229 (35.9) < 0.001
 Ephedrine 99 (26.5) 1,337 (39.0) < 0.001
 Phenylephrine 33 (8.8) 167 (4.9) 0.002
 Norepinephrine 4 (1.1) 25 (0.7) 0.523
 Esmolol 27 (7.2) 139 (4.1) 0.007
 Labetalol 21 (5.6) 55 (1.6) < 0.001
 Nicardipine 25 (6.7) 77 (2.2) < 0.001
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surgical resection of the primary tumor can be ultimately 
curative, it also exposes the patient to an immunologically 
vulnerable period during which the patient is relatively 
more prone to undetectable residual disease or 
micrometastasis. [27] Although it is still largely under 
debate, neuraxial techniques have been suggested to be 
able to improve prognosis after cancer surgery. However, 
the findings of the present retrospective analysis show 
otherwise, where we failed to find any difference in 
recurrence or mortality after curative surgery for gastric 
cancer between patients that received either IV or epidural 
PCA for postoperative analgesia. 
Proposed mechanisms through which regional 
anesthesia and analgesia may influence cancer outcome 
can be summarized into “immunomodulation” and 
“anti-inflammation”. The immunomodulatory and anti-
inflammatory effects of regional anesthesia and analgesia 
can be thought of as the combined output of several 
different mechanisms which include the attenuation of 
sympathetic nervous system stimulation in response to 
surgical stress and postoperative pain, the sparing of the 
need of opioids and therefore the immunosuppressant 
effects of such drugs, and the direct cytotoxic and anti-
inflammatory effects of amide local anesthetics such as 
ropivacaine which was used in all of the patients included 
in our analysis. [27, 28].
However, whether the aforementioned 
immunomodulatory and anti-inflammatory effects of 
neuraxial techniques actually translate into a positive 
effect on cancer outcome is not clear, and the existing 
evidence present conflicting results in various types of 
cancer. [27] This is also true for gastric cancer, where 
epidural anesthesia and/or analgesia are commonly used. 
A rare randomized trial that studied the effect of epidural 
analgesia on cancer prognosis after major abdominal 
surgery concluded that cancer recurrence and mortality 
rates were not different between patients that received 
general anesthesia combined with epidural anesthesia 
Intraoperative fluid
 Colloid 62 (16.6) 561 (16.4) 0.941
 Packed RBC 8 (2.1) 65 (1.9) 0.692
Recurrence 81 (21.7) 585 (17.1) 0.031
Mortality 90 (24.1) 641 (18.7) 0.015
Values are mean ± SD or n (%) of patients, HTN = hypertension, DM = diabetes mellitus
AWD = adenocarcinoma, well differentiated, AMD = adenocarcinoma, moderately differentiated, APD = adenocarcinoma, 
poorly differentiated, SRC = signet ring cell. Pulmonary disease* = History of pulmonary diseases, Cardiac disease† = History 
of cardiac diseases other than hypertension, Renal disease‡ = History of renal diseases, Liver diseaseǁǁ = History of liver 
diseases, Neurologic diseaseǁǁ = History of neurologic diseases including cerebrovascular accidents. 
Figure 1: Flowchart of patient sample selection.
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Table 2: Univariate and multiple regression analysis of variables associated with recurrence after 
open gastrectomy for gastric cancer 
Univariate Analysis Multiple Analysis
Hazard Ratio (95% 
CI) P-value Hazard Ratio (95% CI) P-value
PCA type
 Intravenous 1 1
 Epidural 1.032 (0.818–1.303) 0.789 1.092 (0.859–1.388) 0.471
Age 1.009 (1.002–1.015) 0.007 1.012 (1.005–1.020) 0.001
Sex
 Male 1 1
 Female 0.961 (0.815–1.133) 0.637 1.014 (0.834–1.232) 0.893
Height 0.997 (0.987–1.007) 0.545 0.981 (0.954–1.010) 0.202
Weight 1.002 (0.994–1.009) 0.671 1.005 (0.996–1.014) 0.288
Comorbidities
 HTN 1.116 (0.935–1.333) 0.225 0.974 (0.800–1.185) 0.790
 DM 1.114 (0.898–1.383) 0.325 0.975 (0.772–1.231) 0.829
Cancer stage
 I 1 1
 II 1.364 (0.965–1.927) 0.078 1.330 (0.936–1.890) 0.112
 III 1.867 (1.378–2.528) < 0.0001 1.733 (1.266–2.372) < 0.001
Tumor histology 
 AWD 1
 AMD 0.876 (0.693–1.106) 0.266
 APD 0.910 (0.724–1.143) 0.417
 Mucinous 1.081 (0.688–1.699) 0.735
 SRC 0.884 (0.690–1.133) 0.330
 Other 0.861 (0.544–1.365) 0.525
Lymphovascular invasion 0.973 (0.840–1.126) 0.714
Resection method
 Subtotal 1 1
 Total 1.302 (1.115–1.520) 0.001 1.308 (1.112–1.538) 0.001
Anesthetic 
 Desflurane 1.140 (0.919–1.415) 0.233
 Enflurane 0.474 (0.273–0.824) 0.008 0.603 (0.340–1.072) 0.085
 Isoflurane 1.050 (0.887–1.243) 0.569
 Sevoflurane 0.980 (0.841–1.142) 0.794
 N2O 0.747 (0.590–0.945) 0.015 0.823 (0.643–1.052) 0.120
 Propofol 1% 1.115 (0.934–1.331) 0.228
 Thiopental sodium 0.894 (0.746–1.072) 0.226
Other perioperative drugs
 Aspirin 1.031 (0.257–4.129) 0.966
 NSAIDs 0.905 (0.783–1.045) 0.174
 Ephedrine 1.106 (0.946–1.292) 0.208
 Phenylephrine 1.442 (1.045–1.989) 0.026 1.255 (0.893–1.763) 0.192
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and analgesia, compared to those that received general 
anesthesia with opioid analgesia. [16] However, the 
proportion of patients with gastric cancer was lower than 
15% overall, and approximately 50% of patients were 
those with colorectal cancer. It is difficult to generalize 
its results mainly due to the fact that tumor biology varies 
significantly between organs. Also, while this study 
is significant in that it is probably the only randomized 
trial to date that studied the effect of epidural block with 
follow-up results up to 5 years, the analysis itself was a 
retrospective review of follow-up data from a previous 
RCT. 
Although gastric cancer is the fifth most common 
malignancy and the third leading cause of cancer death 
worldwide, due to its relative uncommonness in Northern 
America and Europe, studies conducted in gastric cancer 
patients are lacking in comparison to studies in colorectal, 
breast, prostate and ovarian cancer. As of today, the 
majority of existing retrospective studies report no 
association between epidural anesthesia and/or analgesia 
and gastric cancer prognosis. Hiller et al. [4] reported 
an association between postoperative epidural analgesia 
and benefit on cancer recurrence and survival following 
surgery for esophageal, but not gastric cancer in 2014. 
A similar study by Cummings et al. [25] also published 
in the same year reported no association between 
postoperative epidural analgesia and reduced recurrence 
or improved survival after resection in gastric cancer 
patients. These results somewhat dampened the earlier 
enthusiasm towards the possible ability of perioperative 
epidural techniques to modulate cancer recurrence. A 
more recent retrospective study that compared combined 
epidural and general anesthesia with general anesthesia 
alone, reported no difference in long-term survival in 
gastric cancer patients [14]. Interestingly, in contrast to 
the aforementioned negative reports, a recent retrospective 
study of 4,218 patients by Wang et al. [15] concluded that 
epidural anesthesia combined with general anesthesia 
and postoperative epidural PCA may be associated with 
improved survival after resection for gastric cancer. 
However, despite having the merit of a largest sample 
size to date, this study only looked at overall survival, 
but not cancer recurrence after surgery. Also, the majority 
of patients included in this study were of advanced stage 
(Stage I = 28.9%, Stage II = 4.3%, Stage III = 66.9%), 
which may have affected their results. The patients of the 
present study showed a relatively more even distribution 
among cancer stages (Stage I = 53.8%, Stage II = 18.1%, 
Stage III = 28.1%) compared to the previous retrospective 
analysis.
Our study is not the first retrospective analysis to 
report negative association between epidural analgesia 
 Norepinephrine 2.953 (1.219–7.153) 0.016 1.866 (0.685–5.082) 0.222
 Esmolol 1.380 (0.990–1.924) 0.058
 Labetalol 1.222 (0.673–2.221) 0.501
 Nicardipine 1.570 (0.940–2.624) 0.085 1.454 (0.859–2.460) 0.163
Intraoperative fluid
 Colloid 1.076 (0.892–1.297) 0.444
 Packed RBC 1.097 (0.735–1.637) 0.650
CI = Confidence Interval PCA = patient controlled analgesia, HTN = hypertension, DM = diabetes mellitus, RBC = red blood cells.
Figure 2: Kaplan–Meier curves for 5-year recurrence and mortality.
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Table 3: Univariate and multiple regression analysis of variables associated with mortality after 
open gastrectomy for gastric cancer 
Univariate Analysis Multiple Analysis
Hazard Ratio (95% 
CI) P-value Hazard Ratio (95% CI) P-value
PCA type
 Intravenous 1 1
 Epidural 0.818 (0.655–1.021) 0.075 0.695 (0.429–1.125) 0.138
Age 1.007 (1.001–1.013) 0.030 1.015 (1.003–1.027) 0.016
Sex
 Male 1 1
 Female 1.110 (0.945–1.304) 0.205 0.905 (0.590–1.389) 0.649
Height 0.990 (0.981–0.999) 0.028 0.989 (0.964–1.014) 0.385
Weight 0.994 (0.986–1.001) 0.086 0.997 (0.982–1.012) 0.689
Comorbidities
 HTN 1.029 (0.878–1.207) 0.720 0.753 (0.555–1.021) 0.068
 DM 1.130 (0.933–1.369) 0.210 1.148 (0.801–1.645) 0.452
Cancer stage
 I 1 1
 II 1.338 (1.016–1.762) 0.038 1.745 (1.146–2.657) 0.009
 III 1.717 (1.367–2.156) < 0.0001 2.193 (1.476–3.257) < 0.001
Tumor histology 
 AWD 1
 AMD 0.949 (0.663–1.358) 0.774
 APD 1.220 (0.860–1.731) 0.265
 Mucinous 0.963 (0.591–1.568) 0.879
 SRC 1.157 (0.795–1.684) 0.447
 Other 1.103 (0.651–1.867) 0.715
Lymphovascular invasion 1.198 (1.024–1.401) 0.025 0.865 (0.657–1.139) 0.302
Resection method
 Subtotal 1 1
 Total 1.350 (1.165–1.565) < 0.0001 1.473 (1.155–1.877) 0.002
Anesthetic 
 Desflurane 1.149 (0.928–1.425) 0.203
 Enflurane 0.418 (0.235–0.745) 0.003 0.549 (0.297–1.012) 0.055
 Isoflurane 0.921 (0.782–1.083) 0.318
 Sevoflurane 1.118 (0.964–1.296) 0.140
 N2O 0.761 (0.610–0.950) 0.016 1.087 (0.824–1.433) 0.556
 Propofol 1% 1.017 (0.864–1.198) 0.837
 Thiopental sodium 1.059 (0.895–1.252) 0.505
Other perioperative drugs
 Aspirin 1.535 (0.493–4.775) 0.459
 NSAIDs 0.846 (0.729–0.981) 0.027 1.074 (0.838–1.376) 0.573
 Ephedrine 1.151 (0.993–1.334) 0.063 1.076 (0.836–1.385) 0.569
 Phenylephrine 1.455 (1.122–1.887) 0.005 2.070 (1.169–3.664) 0.013
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and gastric cancer prognosis. However, the present 
study seems to have great merit in that it is the first to 
include a very homogeneous group of patients from a 
reliable database of a high-volume center. Overlooking 
the importance of the nature of the surgical procedure 
as well as surgical technique can easily lead to incorrect 
interpretations in cancer patients. By including a 
homogeneous group of patients that underwent curative 
surgery, the present study was able to analyze the effect of 
epidural analgesia on recurrence after complete resection. 
Moreover, standardized extended (D2) lymphadenectomy 
was employed as a uniform surgical technique in all 
patients that were included in our analysis. Compared to 
limited (D1) lymphadenectomy, the D2 procedure has been 
proven to be associated with lower recurrence and gastric-
cancer-related mortality, and is currently recommended as 
the surgical approach of choice for patients with curable 
gastric cancer. [29] The good quality database and further 
PSM analysis that was used in the present study has been 
able to increase the reliability of our results. Whether 
epidural analgesia is able to affect length of survival or 
mortality in patients undergoing palliative or non-curative 
surgery requires future studies. 
Despite the negative results of our study, it is difficult 
to conclude that regional techniques are not related to 
outcome after gastrectomy. One may suspect that isolated 
use of postoperative epidural analgesia without combining 
intraoperative epidural anesthesia is insufficient to induce 
effective immunomodulatory or anti-inflammatory effects. 
It seems most important to acknowledge that epidural 
analgesia is among the many different factors associated 
with perioperative anesthesia care that have been suggested 
to have effect on tumor progression and cancer prognosis. 
[27] It would be a futile attempt to improve cancer prognosis 
with a single drug or procedure, and therefore clinicians 
should be able to achieve good analgesia, and ameliorate 
perioperative stress and inflammation overall. [30] 
The association between the use of norepinephrine 
and phenylephrine and greater hazard for mortality is 
most likely due to greater hemodynamic instability and 
hence the need for more vasopressors in patients with 
poorer general condition. Due to the retrospective design 
of the present analysis, we cannot conclude whether such 
drugs are definite causes of mortality or whether they 
are simply markers of worse clinical outcome. Among 
other perioperative drugs of interest, both aspirin [31, 32] 
and NSAIDs [33] showed no association with reduced 
recurrence or mortality. Interestingly, the use of labetalol, 
a non-selective β adrenergic antagonist, was found to be 
associated with greater mortality after gastrectomy which 
is in contrary to previous reports. [34–36] However, the 
confidence interval was very wide, which indicates that our 
sample size was too small to draw conclusions in this aspect. 
The major limitation of the present study is its 
retrospective nature, and thus its susceptibility to chance, 
bias and other confounding factors. However, we were 
 Norepinephrine 1.740 (0.982–3.081) 0.058 2.638 (1.040–6.690) 0.041
 Esmolol 1.252 (0.922–1.701) 0.150
 Labetalol 1.904 (1.099–3.299) 0.022 10.623 (1.31–86.135) 0.027
 Nicardipine 1.366 (0.865–2.156) 0.181
Intraoperative fluid
 Colloid 0.859 (0.724–1.020) 0.083 0.758 (0.575–0.999) 0.050
 Packed RBC 1.300 (0.929–1.818) 0.126
CI = Confidence Interval PCA = patient controlled analgesia, HTN = hypertension, DM = diabetes mellitus, RBC = red blood cells.
Table 4: Association between PCA type and post-surgery prognosis in 1-to-1 propensity score-
matched gastric cancer patients that underwent open gastrectomy 
Outcome IV PCA(n = 373)
Epidural PCA
(n = 373)
Hazard Ratio
(95% CI) P-value
Recurrence 1.098 (0.756–1.596) 0.623
 No 292 (78.3) 304 (81.5)
 Yes 81 (21.7) 69 (18.5)
Mortality 0.855 (0.391–1.869) 0.695
 No 283 (75.9) 291 (78.0)
 Yes 90 (24.1) 82 (22.0)
Values are n (%) of patients CI = Confidence Interval, PCA = patient controlled analgesia.
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able to include a relatively large number of patients from 
a single center, high-quality database in our analysis, 
and also performed propensity score matching with the 
available covariates to overcome potential selection 
bias somewhat. Although definitive data can only be 
provided by future RCTs, the results after propensity 
score matching in the present study should be able to add 
valuable insight to this debatable issue. Another limitation 
is that it is unclear how long the epidural catheters and 
PCA devices were maintained, and whether postoperative 
epidural analgesia was prematurely discontinued in 
patients included in the present analysis. Of note, it has 
been routine practice to start epidural PCA machines at 
the end of surgery and maintain infusion for 3 days in 
patients undergoing gastrectomies at our hospital. Also, 
intraoperative epidural infusions are rarely used. Therefore 
the results of the present study should be interpreted as 
a comparison between postoperative analgesic methods, 
and not as anesthesia. However, intermittent or complete 
discontinuation of epidural infusions due to hypotension or 
side effects of opioids are not uncommon in postoperative 
patients, and the absence of this data may have affected 
the results of our analysis. 
In conclusion, postoperative epidural PCA does not 
seem to be associated with reduced recurrence or lower 
mortality in patients undergoing open curative gastrectomy 
for gastric cancer. Epidural analgesia should be employed 
as part of a comprehensive perioperative management plan, 
but should not be relied on as a beneficial factor for the 
prognosis after curative surgery in gastric cancer patients.  
MATERIALS AND METHODS
Study population and design
This study is a retrospective analysis of patients 
that underwent open gastrectomy for gastric cancer with 
either IV or epidural PCA for postoperative pain control. 
The study protocol was approved by the Institutional 
Review Board and Hospital Research Ethics Committee 
of Severance Hospital, Yonsei University Health System 
(IRB #4-2017–0392). The data collected for this study 
was from the electrical medical records of patients 
that underwent surgery between November 2005 and 
December 2010 at a single institution. Patients that 
received pre-operative chemotherapy or those that 
underwent non-curative surgery, cases that started as 
laparoscopic procedures but converted to laparotomy, 
electronic charts with unclear method of postoperative 
analgesia, and mortality cases that occurred within 30 days 
after surgery were excluded from analysis. 
Retrieved demographic data of the patients 
included age, sex, height, weight, and comorbidities 
such as hypertension (HTN), diabetes mellitus (DM), 
pulmonary diseases, etc. In addition to type of PCA, 
cancer stage, extent of gastrectomy, type of anesthetic, 
common intraoperative drugs, and intraoperative colloid 
administration and red blood cell (RBC) transfusion were 
also analyzed as variables possibly associated with the 
prognosis of gastric cancer after open gastrectomy. 
Statistical analysis 
The primary outcome of this study was to compare 
the recurrence rate of gastric cancer between the two 
postoperative analgesia methods. Demographic and 
perioperative characteristics were analyzed using the 
Student’s t-test for continuous variables and the chi-square 
test for categorical variables. Potential factors affecting 
cancer recurrence and mortality after gastrectomy were 
analyzed by the Cox proportional hazards model, and the risk 
of each variable was calculated as hazard ratio (HR) and 95% 
confidence intervals (CIs). After screening for potentially 
significant variables with univariate analysis, multiple Cox 
regression analysis was done by including factors with 
P values < 0.2. Overall survival rates during the study 
period, and difference between survival curves according 
to PCA route were examined with the Kaplan–Meier log-
rank survival analysis method. Propensity score matching 
(PSM) was done to reduce selection bias, and confounders 
used for PSM included age, sex, body mass index, presence 
of DM and HTN. After 1:1 matching with propensity 
scores calculated with logistic regression analysis with 
aforementioned confounding factors, the risk of recurrence 
and mortality with each type of PCA was analyzed with 
conditional Cox proportional hazard regression. P values 
less than 0.05 were considered as statistically significant. All 
analyses were done with SAS version 9.4. 
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CI: confidence interval; DM: diabetes mellitus; HR: 
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